TLPH · Talphera, Inc. · Executive Compensation
$1.11
-0.05 (-4.31%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$61.25M
Shares
51.91M
Volume · Oct 6
115.79K
Avg daily vol (3M)
268.85K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Vincent Angotti | CEO | $1,117,277 |
| Vincent J. Angotti | Chief Executive Officer | $1,117,277 |
| Raffi Asadorian | Chief Financial Officer | $727,309 |
| Shakil Aslam | Chief Medical Officer | $654,840 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Vincent Angotti | CEO | $1,038,992 |
| Vincent J. Angotti | Chief Executive Officer | $1,038,992 |
| Raffi Asadorian | Chief Financial Officer | $709,857 |
| Badri Dasu | Chief Engineering Officer | $575,959 |
| Shakil Aslam | Chief Medical Officer | $529,242 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | Chief Executive Officer | $1,211,994 |
| Vincent Angotti | CEO | $1,211,994 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $814,270 |
| Raffi Asadorian | Chief Financial Officer | $742,609 |
| Badri Dasu | Chief Engineering Officer | $602,166 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | Chief Executive Officer | $1,297,016 |
| Vincent Angotti | CEO | $1,297,016 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $822,400 |
| Raffi Asadorian | Chief Financial Officer | $755,144 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Vincent Angotti | CEO | $2,447,954 |
| Vincent J. Angotti | Chief Executive Officer | $2,447,954 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $1,083,507 |
| Raffi Asadorian | Chief Financial Officer | $1,024,610 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Vincent Angotti | CEO | $1,765,522 |
| Vincent J. Angotti | Chief Executive Officer | $1,765,522 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $962,122 |
| Raffi Asadorian | Chief Financial Officer | $890,716 |
| Badri Dasu | Chief Engineering Officer | $686,353 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Vincent J. Angotti | Chief Executive Officer | $2,125,052 |
| Vincent Angotti | CEO | $2,125,052 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $1,083,333 |
| Raffi Asadorian | Chief Financial Officer | $1,013,492 |
| Badri Dasu | Chief Engineering Officer | $776,258 |
| Lawrence G. Hamel | — | $776,018 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Vincent Angotti | CEO | $1,738,845 |
| Vincent J. Angotti | Chief Executive Officer | $1,738,845 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $1,063,956 |
| Raffi Asadorian | Chief Financial Officer | $907,235 |
| Badri Dasu | Chief Engineering Officer | $734,208 |
| Former Chief Development | Officer | $688,617 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Vincent Angotti | CEO | $2,353,923 |
| Vincent J. Angotti | Chief Executive Officer | $2,353,923 |
| Pamela Palmer | M.D., Ph.D. Chief Medical Officer | $874,093 |
| Raffi Asadorian | Chief Financial Officer | $606,287 |
| Former Chief Development | Officer | $595,179 |
| Badri Dasu | Chief Engineering Officer | $595,179 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mark Wan | Class III director | Appointed | 2026-06-23 |
| Joseph Todisco | Class III director | Appointed | 2026-06-23 |
| Marina Bozilenko | Class III director | Appointed | 2026-06-23 |
| Abhinav Jain | Class II director | Appointed | 2025-10-24 |
| Stephen J. Hoffman | Class II director | Appointed | 2025-10-24 |
| Vincent J. Angotti | Class II director | Appointed | 2025-10-24 |
| Joseph Todisco | Class III member of the board of directors and member of the compensation committee | Appointed | 2025-10-16 |
| Shakil Aslam | Chief Development Officer | Appointed | 2024-08-14 |
| Shakil Aslam | Chief Medical Officer | Appointed | 2024-08-14 |
| Pamela P. Palmer, MD, PhD | Chief Medical Officer | Resigned | 2024-08-14 |
| Jill Broadfoot | Class I director | Appointed | 2024-06-24 |
| Adrian Adams | Class I director | Appointed | 2024-06-24 |
| Howard B. Rosen | member of the board of directors | Resigned | 2024-03-01 |
| Pamela P. Palmer, M.D., Ph.D. | member of the Company's board of directors | Resigned | 2024-03-01 |
| Richard Afable, M.D. | member of the board of directors | Resigned | 2024-03-01 |
| Abhinav Jain | Class II Director | Appointed | 2024-01-22 |
| Mark Wan | Class III director | Appointed | 2023-10-10 |
| Howard B. Rosen | Class III director | Appointed | 2023-10-10 |
| Marina Bozilenko | Class III director | Appointed | 2023-10-10 |